[PARP inhibitors: significant progress in cancer therapy].
Fiche publication
Date publication
mars 2011
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DANTZER Françoise, Pr NOEL Georges, Dr SCHREIBER Valérie
Tous les auteurs :
Dantzer F, Noel G, Schreiber V
Lien Pubmed
Résumé
Poly(ADP-ribosyl)ation is a post-translational modification of proteins catalyzed by poly(ADP-ribose) polymerases (PARPs). In response to genotoxic stress, PARP-1 senses DNA breaks and through the synthesis of poly(ADP-ribose) restores genome integrity by stimulating a base excision and single-strand break repair process. These properties highlight the innovative potency of PARP inhibitors to target cancer cells in their repair capacity. They open the way to promising therapeutic strategies aimed to combine PARP inhibitors with DNA-damaging chimio- or radiotherapy and as single agents for the treatment of BRCA mutation-associated tumors. The benefits to potential risks ratio of these approaches will be discussed.
Référence
Bull Cancer. 2011 Mar 1;98(3):277-90.